

**Chammas & Marcheteau advises Spore.Bio
in its €23 million funding round (Biotechnology/AI)**

Chammas & Marcheteau advised Spore.Bio in its €23 million Series A financing round led by Singular with the participation of Station F, First Kind, the US-based Point 72 Ventures and historical investors, in partnership with Institut Pasteur.

Founded in 2022, Spore.Bio is building the world's first real-time pathogen AI-driven detection device for food factories, reducing the sampling time required to detect bacteria from 20 days to just a few minutes and being able to be carried out directly in the factory instead of sent to external laboratories.

This new financing will enable the deeptech company to double its workforce and strengthen its international presence.

The **Chammas & Marcheteau** team consisted of **Lola Chammas** (partner), **Romain Penloup** and **Julien Delacroix** (associates).

About Chammas & Marcheteau

Chammas & Marcheteau is a Paris-based independent law firm that advises companies, investment funds and entrepreneurs on their transactions and development strategies in France and abroad. With more than 60 specialists in business law, including 16 partners, the Firm offers its clients expertise in Private Equity, Mergers & Acquisitions, Funds and Financial Services, Corporate, Restructuring and Turnaround, Tax, Intellectual Property and Information Technology, Employment Law, Real Estate and Business Litigation.